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Chandree L. Beaulieu,2 FORGE Canada Consortium,16 Jacek Majewski,4 Dennis E. Bulman,2
Mark O’Driscoll,3 Kym M. Boycott,1,2 and A. Micheil Innes14,15,*
SHORT syndrome is a rare, multisystem disease characterized by short stature, anterior-chamber eye anomalies, characteristic facial fea-
tures, lipodystrophy, hernias, hyperextensibility, and delayed dentition. As part of the FORGE (Finding of Rare Disease Genes) Canada
Consortium, we studied individuals with clinical features of SHORTsyndrome to identify the genetic etiology of this rare disease.Whole-
exome sequencing in a family trio of an affected child and unaffected parents identified a de novo frameshift insertion, c.1906_1907insC
(p.Asn636Thrfs*18), in exon 14 of PIK3R1. Heterozygous mutations in exon 14 of PIK3R1 were subsequently identified by Sanger
sequencing in three additional affected individuals and two affected family members. One of these mutations, c.1945C>T
(p.Arg649Trp), was confirmed to be a de novo mutation in one affected individual and was also identified and shown to segregate
with the phenotype in an unrelated family. The other mutation, a de novo truncatingmutation (c.1971T>G [p.Tyr657*]), was identified
in another affected individual. PIK3R1 is involved in the phosphatidylinositol 3 kinase (PI3K) signaling cascade and, as such, plays an
important role in cell growth, proliferation, and survival. Functional studies on lymphoblastoid cells with the PIK3R1 c.1906_1907insC
mutation showed decreased phosphorylation of the downstream S6 target of the PI3K-AKT-mTOR pathway. Our findings show that
PIK3R1mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve down-
regulation of the PI3K-AKT-mTOR pathway.SHORT syndrome (MIM 269880) is a rare disorder charac-
terized by short stature, hyperextensibility of joints
and/or hernias, ocular depression, Rieger anomaly, and
delays of tooth eruption.1 Although these features provide
the condition’s acronym, they do not capture the full
range of clinical features, which can include a recogniz-
able facial gestalt (triangular facies, lack of facial fat, and
hypoplastic nasal alae with overhanging columella), a
near universal partial lipodystrophy, insulin resistance,
nephrophrocalcinosis, and hearing deficits, among
many others.2–7 Notably, both developmental milestones
and cognition are normal for individuals with SHORT
syndrome.3
The first description of SHORT syndrome was of a sibling
pair whose parents displayed no obvious features.1
This has been followed by several reports of sporadic
occurrences, suggesting an autosomal-recessive or de
novo dominant mode of inheritance.6 However, there
have also been several reports of parent-child transmis-
sions, including male-to-male transmission, consistent
with an autosomal-dominant inheritance pattern for
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cant contribution for de novo dominant mutations.
Specific genes have been suggested to play a role in the
etiology of SHORT syndrome. PITX2 (MIM 601542) was
highlighted in an individual with Rieger anomaly and syn-
dromic features including lipoatrophy, hyperextensibility,
a ventricular septal heart defect, and dysmorphic facial
features.10 This individual had a familial chromosomal
translocation involving PITX2.10 Another individual with
eye anomalies and short stature was found by microarray
to have a large deletion spanning PITX2 and several other
genes.11 BMP4 (MIM 112262) is associated with micro-
phthalmia and has been reported to be deleted, along
with 14 other genes at 14q22.2, in a single individual diag-
nosed with SHORT syndrome.12 Although they appear to
have a syndrome related to Axenfield-Rieger anomaly,
affected individuals with PITX2 and BMP4 mutations10,12
do not have the characteristic facial gestalt shared by the
individuals in the original and subsequent descriptions
of SHORT syndrome.1–4,6,7,13
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identifying genetic mutations for rare childhood dis-
eases.14–16 We ascertained individuals with SHORT syn-
drome by contacting the members of the FORGE Canada
Consortium and selected international colleagues and
asking whether the physicians were aware of any
individual(s) diagnosed with SHORT syndrome. Affected
individuals and family members were recruited from
Medical Genetics Clinics in North America, Israel, and
the United Kingdom. Approval of the study design was ob-
tained from the institutional research ethics board at the
Children’s Hospital of Eastern Ontario, and free and
informed consent was obtained from each study subject
(or parent, if appropriate) prior to enrollment. Each
individual was assessed by a medical geneticist, ophthal-
mologist, and/or pediatrician. Affected individuals 2 and
5 were previously published as cases of SHORT syndrome
with associated nephrocalcinosis.5 The clinical description
of the affected individuals is presented in Table 1. DNA
was extracted according to standard protocols. Paternity
was confirmed by the genotyping of nine polymorphic
simple-tandem-repeat markers.
We performed exome capture and high-throughput
sequencing of samples for affected individual 1 and her
two unaffected parents (trio design) and for affected indi-
vidual 2 (simplex case). Target enrichment for the samples
was performed with the Agilent SureSelect 50 Mb (V3) All
Exon Kit. Sequencing (Illumina HiSeq) generated >14 Gbp
of 100 bp paired-end reads per sample. Read alignment,
variant calling, and annotation were done as for previous
FORGE projects17 with a pipeline based on the Burrows-
Wheeler Aligner (BWA), Picard, ANNOVAR, and custom
annotation scripts. We removed adaptor sequences and
quality trimmed reads by using the FASTX-Toolkit and
then used a custom script to ensure that only read pairs
with both mates present were subsequently used. Reads
were aligned to UCSC Genome Browser hg19 with BWA
0.5.9,18 and indel realignment was done with the Genome
Analysis Toolkit (GATK).19 Duplicate reads were then
marked with Picard and excluded from downstream ana-
lyses. We assessed coverage of Consensus Coding Sequence
(CCDS) bases by using the GATK, which showed that all
samples had >92% of CCDS bases covered by at least 20
reads. For each sample, single-nucleotide variants (SNVs)
and short insertions and deletions (indels) were called
with SAMtools pileup20 with the extended base-align-
ment-quality adjustment (-E) and were then quality
filtered so that at least 20% of reads supported the variant
call. We annotated variants by using both ANNOVAR21
and custom scripts to identify whether they affect pro-
tein-coding sequence and whether they are present in
dbSNP132, the 1000 Genomes data set (2012/04 release),
the 6,500 exomes in the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project Exome
Variant Server (data downloaded October 3, 2012; see
Web Resources), or in approximately 800 exomes previ-
ously sequenced at the McGill University and Genome
Quebec Innovation Centre.The AmFirst, we analyzed the data from affected individual 1
and her unaffected parents. Two de novo nonsynonymous
variants were detected in the affected individual, and
they were found to be absent in both parents. The
first, SNV c.3656C>G (p.Ser1219Cys) (RefSeq accession
number NM_001164496.1) in WDR52, is predicted to be
a polymorphism by MutationTaster (see Web Resources).
The second, frameshift insertion c.1906_1907insC
(p.Asn636Thrfs*18) (RefSeq NM_181523.2) in exon 14 of
PIK3R1, generates a stop codon in the region encoding
amino acid residue 654 and is expected to produce prema-
ture truncation of p85a, the longest protein isoform
encoded by PIK3R1. No genes with two obvious deleterious
mutations—one inherited from each parent—were de-
tected.
Next, we assessed the sequencing results of affected indi-
vidual 2 for any rare variants present in a heterozygous
state. No variants were seen in PIK3R1 or WDR52 for
affected individual 2; several variants were highlighted as
rare and were confirmed by Sanger sequencing. All were
found to be inherited and hence were unlikely candidate(s)
for causing SHORT syndrome in this affected individual.
There was excellent coverage for PIK3R1 (>503 across all
exons) and no evidence of any structural variant. PIK3R1
was investigated by Sanger sequencing in affected individ-
uals 3–5. In exon 14 of PIK3R1, affected individual 3 was
found to have a nonsense mutation (c.1971T>G
[p.Tyr657*]) absent in both parents, and affected individ-
ual 4 was found to have a missense mutation
(c.1945C>T [p.Arg649Trp]) absent in both parents and
predicted to be damaging by PolyPhen. Affected individual
5,5 as well as his affected mother and brother,8 has been
previously described. These three affected individuals
were found to have the same missense mutation,
c.1945C>T (p.Arg649Trp), as affected individual 4, and
this recurrent mutation occurs within the context of a
CpG motif. These mutations are not represented in
dbSNP131, 1000 Genomes, or the NHLBI Exome Variant
Server. The observation of rare mutations in the same
exon of PIK3R1 in four of five affected individuals, the
recurrence of the samemutation in two unrelated, affected
individuals, and a consistent inheritance pattern in a
family and de novo cases together provide strong genetic
evidence that we have identified the molecular cause of
SHORT syndrome.
The identification of a disease-causing mutation in a
disorder such as SHORT syndrome can be a difficult
task given the rarity of affected individuals and their
varied clinical presentations. Despite the similar clinical
presentation, we did not identify a PIK3R1 mutation
in affected individual 2. All the affected individuals
included in our study display features of SHORT syn-
drome (Table 1). Re-evaluation of the phenotype of
affected individual 2 confirmed that he shows several
of the core features of SHORT syndrome (short stature,
inguinal hernias, delayed dentition, a lack of subcutane-
ous fat, and an anterior-chamber ocular defect; Table 1).erican Journal of Human Genetics 93, 158–166, July 11, 2013 159
Table 1. Clinical Characteristics of Individuals with SHORT Syndrome
Affected Individual 1 Affected Individual 2 Affected Individual 3 Affected Individual 4 Affected Individual 5 Affected Individual 6 Affected Individual 7
Age at assessment 2 years 10 years 10.4 years birth to 18 years 4 years 32 years at birth
Gender female male male male male female male
PIK3R1 mutation c.1906_1907insC - c.1971T>G c.1945C>T c.1945C>T c.1945C>T c.1945C>T
Growth
Birth weight 1.556 kg at 365 weeks 0.760 kg at 32 weeks 2.22 kg at 40 weeks 2.52 kg at 38 weeks 2.27 kg at term 2.55 kg at term 2.18 kg at term
Height (percentile) 76.5 cm (<3rd) 120 cm (<3rd) 126 cm (3rd) 132.5 cm at 11 years (5th);
160 cm at 18 years (<3rd)
122.3 cm at 11 years
(<3rd)
148.5 cm (<3rd) 45 cm
Weight (percentile) 8 kg (<3rd) not reported 21.8 kg (<3rd) 23.5 kg at 11 years (<3rd);
43 kg at 18 years (<3rd)
17.9 kg at 11 years (<3rd) 44 kg (3rd) 2.18 kg
Head circumference
(percentile)
43 cm (<3rd) not reported 51.5 cm (25th) 45.5 cm at 20 months
(3rd)
49 cm (25th) 49.5 cm (<3rd) 34 cm
Bone age normal delayed by 2.5 years delayed by 24 months delayed not reported not reported not reported
Connective Tissue
Hyperextensibility no yes; especially small
joints
yes; especially small
joints
no none reported no NA
Hernias no inguinal hernia no no none reported no no
Facies
Triangular facies yes yes yes yes yes yes yes
Ocular depression yes yes yes yes yes yes yes
Aged appearance yes yes yes yes yes to hands to hands
Dimple yes no no yes yes no no
Hypoplastic ala nasi yes yes yes yes yes yes yes
Eye Anomalies
Rieger anomaly right optic-pit anomaly right-sided; temporal;
posterior; embryotoxin
not typical possible no no no
Glaucoma no no no no no no no
Other anterior-chamber
anomalies
no no atypical irises with
hypoplastic appearance
on transillumination;
poorly dilating,
constricting pupils
no iridogoniodysgenesis hypoplasia of iris stroma
on transillumination
no
(Continued on next page)
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Table 1. Continued
Affected Individual 1 Affected Individual 2 Affected Individual 3 Affected Individual 4 Affected Individual 5 Affected Individual 6 Affected Individual 7
Dental
Teething delays or other yes yes; fusion of central
and lateral incisors
delayed eruption of
teeth; overcrowded
teeth with micrognathia
yes not reported delays with primary
dentition; crowding
NA
Other Common Features
Development and
cognition
normal normal range speech delay normal normal normal normal
Insulin resistance or
diabetes
no no no no no no no
Lipodystophy yes yes yes yes no hands hands
Hearing loss no no no yes no no unilateral
Radiological features none reported left acetabular dysplasia;
right Perthes disease
slender, narrow iliac
wings; slender long
bones; ‘‘drumstick’’
distal phalanges;
narrow upper thorax
none reported none reported none reported none reported
Other - hypercalciuria; ASD;
VSD; patent ductus
arteriosus
vitiligo since age 7 years;
poor response to growth
hormone; behavioral
problems
- VSD; anorectal atresia;
nephrocalcinosis;
neuropathic bladder
- -
Previously reported
in the literature
no yes5 no no yes5 yes8 yes8
The following abbreviations are used: NA, not applicable; ASD, atrial septal defect; and VSD, ventricular septal defect.
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Figure 1. Facial Features of Individuals
Clinically Diagnosed with SHORT Syn-
drome
(A–F) Photographs of affected individuals
1 (A and B), 3 (C and D), and 4 (E and F)
capture the core facial gestalt, including
the broad triangular facies, deep-set eyes,
hypoplastic alae nasae, low-hanging colu-
mella, and downturned mouth.
(G) Photograph of individual 2, who has a
diagnosis of SHORT syndrome.5 This indi-
vidual has several features of SHORT syn-
drome; however, he appears to lack the
facial features of the individuals in (A)–
(F). Specifically, his face does not appear
to be as triangular, and his eyes are not as
deep set. His columella is not low hanging,
and the ala nasi are not overly hypoplastic.
His mouth is not downturned, and he does
not have obvious micrognathia. This
image was reproduced with permission
from John Wiley & Sons (license number
3112610845148).However, his facial features appear distinct from those
of the mutation-positive individuals (Figure 1G). The
key facial features present in the mutation-positive
individuals include a triangular face, deep-set eyes,
hypoplasic alae nasae, low-hanging columella, and a
downturned mouth (Figures 1A–1F). It appears that
individual 2 does not have SHORT syndrome given the
lack of a PIK3R1 mutation and the recognizable facial
features. This suggests that SHORT syndrome is a highly
specific diagnosis and that it relies heavily on the facial
gestalt.
PIK3R1 encodes the regulatory subunit of PI3K, specif-
ically the predominant regulatory subunit p85a, as well
as the lesser isoforms p50a and p55a.22 The latter two
isoforms are localized in the liver and skeletal muscle,162 The American Journal of Human Genetics 93, 158–166, July 11, 2013respectively.23 p85a is ubiquitous
and binds to PI3K’s catalytic subunit
(p110a), negatively regulating its
kinase activity. In order for p85a
to perform its regulatory role, it first
requires its Src homology 2 (SH2)
domains to be phosphorylated. This
can occur by its binding to insulin-
responsive substrate (IRS) proteins,
by its direct binding to a receptor
tyrosine kinase, or by its phosphory-
lation via the RAS-GTP pathway.24
There are two SH2 domains in
PI3K, and the amino acid alterations
identified in the individuals with
SHORT syndrome are located in the
C-terminal SH2 domain (Figure 2).
This SH2 domain is also present
in the p50a and p55a isoforms. A
lymphoblastoid cell line (LCL) was
able to be established from affectedindividual 1 (with c.1906_1907insC [p.Asn636Thrfs*18])
for functional analysis. LCLs were not available for
affected individuals 3 or 4 or for individuals from the
family of individual 5. Immunoblot analysis showed that
the levels of the p85a-specific isoform were approximately
50% lower in extracts than in control samples; in addition,
extracts from individuals with hemimegalencephaly
caused by activating mutations in PIK3R2 and PIK3CA
were available, and the findings were consistent with a
heterozygous truncating PIK3R1 mutation (Figure 3).
Further, immunoblot analysis using a pan-p85 antisera
uniquely identified a smaller product in LCL extracts
of affected individual 1; they were consistent in size
with the expected truncation due to p.Asn636Thrfs*18
(Figure 3). Levels of the p110a PI3K catalytic subunit
Figure 2. PIK3R1 Mutations in Families Affected by SHORT Syndrome
(A) Family pedigrees and the heterozygous mutations identified in PIK3R1 (RefSeq NM_181523.2).
(B) Electropherograms showing themutation position in the father (top), mother (middle), and affected child (bottom). That of family 5
shows the mutation position in the mother, brother, and proband.
(C) A schematic of PI3K demonstrates the position of the substitutions and truncations in the SH2 domains of the protein. The alter-
ations in red are those from the literature25,26 and are not associated with SHORT syndrome.appeared normal, in keeping with the costabilizing inter-
action between p110a and p85a (Figure 3). Interestingly,
we found that levels of phospho-S6 (Ser240 and Ser244)
were lower in extracts from the LCLs of affected individual
1 than in those from control LCLs, suggestive of
suppressed signal transduction in the PI3K-AKT-mTOR
pathway (Figure 3).
Another alteration that has been described in PI3K is a
substitution disrupting the N-terminal SH2 domain in an
individual with acanthosis nigrecans and severe insulin
resistance.25,28 Recently, there has been a report of an indi-
vidual with agammaglobulinemia, absent B lineage cells,
and a history of colitis and absent p85a resulting from a
mutation in exon 6 of PIK3R1.26 However, isoforms p50a
and p55a were still transcribed because the mutation was
upstream of the p50a and p55a promoter site.26 TheseThe Amfindings suggest phenotypic heterogeneity for mutations
within this gene.
How mutations in PIK3R1 result in the multisystem
phenotype of SHORT syndrome remains unknown.
Although insulin resistance might be hypothesized to be
an upstream consequence of impaired PI3K activation, it
is not universal among individuals with SHORT syndrome
and is not a feature of the four affected individuals reported
here, although this feature might develop with time. Mice
with a targeted deletion of Pik3r1 show a paradoxical in-
crease in insulin sensitivity and episodes of hypoglyce-
mia.29 Importantly, it was observed that the other isoforms
(e.g., p50a) encoded by Pik3r1 were upregulated in these
mice and most likely caused the disturbance in insulin
homeostasis.29 Deletion of all isoforms (p85a, p55a, and
p50a) also results in hypoglycemia, liver necrosis, anderican Journal of Human Genetics 93, 158–166, July 11, 2013 163
Figure 3. Immunoblot Analysis from LCL
Extracts Derived from Individuals with
SHORT Syndrome and Hemimegalence-
phaly
(A) The upper panel shows p85a-specific
levels (top band) in extracts from the
control, individual 1 (c.1906_1907insC
[p.Asn636Thrfs*18]), and two previously
described individuals with hemimegalen-
cephaly. The latter two individuals exhibit
hyperactivating mutations in PIK3R2
(c.1117G>A [p.Gly373Arg]), encoding
the p85b regulatory subunit of PI3K, and
PIK3CA (c.1359_1361del [p.Glu453*]), en-
coding the p110a catalytic subunit of
PI3K.27 Themiddle panel shows the results
of using a pan-p85 antibody capable of
detecting the p85a isoform (encoded by
PIK3R1), as well as p85b (encoded by
PIK3R2) and p55g (encoded by PIK3R3). A truncated product (red arrow) was detected in extracts from individual 1 only
(p.Asn636Thrfs*18). Both p85a and p110a directly interact and costabilize. The lower panel shows a band corresponding to p110a in
LCLs from individual 1, potentially suggestive of stable interaction.
(B) Phosphorylation of S6 (by S6 kinase), which is directly activated bymTOR, is a terminal readout of PI3K-AKT-mTOR-pathway activity.
Titration of whole-cell extract shows that compared to control extracts, those from individual 1 exhibit reduced S6 phosphorylation on
serine 240 and 244. Cells from an individual with a PIK3CAmutation and hemimegalencephaly show elevated S6 phosphorylation, as
previously demonstrated.27 These data are suggestive of diminished signaling through this pathway in the LCLs of individual 1.perinatal lethality in homozygous mice, suggesting that
the p85a isoform is necessary for normal development.23
Upon activation of cell-surface receptors, PI3K catalyzes
the phosphorylation of phosphatidylinositol (4,5) bis-
phosphate (PtdIns(4,5)P2) and generates PtdIns (3,4,5)P3,
an important lipid messenger that stimulates the localized
surface membrane recruitment of important downstream
kinases, including PDK1 and AKT, as part of the signal
transduction cascade. PTEN phosphatase, a well-studied
tumor suppressor, acts in opposition to PI3K by converting
PtdIns (3,4,5)P3to PtdIns(4,5)P2 to finely regulate the
amplitude and duration of signaling.30 Loss of PTEN func-
tion results in the inappropriate activation of the AKT-
mTOR pathway.30 Constitutional mutations in PTEN
(MIM 601728) are seen in disorders such as Cowden
syndrome (MIM 158350) and Banayan-Riley-Ruvulcaba
syndrome (MIM 153480), which are characterized by
overgrowth and a predisposition to malignancy. More
recently mosaic or germline mutations resulting in hyper-
activation of this pathway have been implicated in Proteus
syndrome (MIM 176920), megalencephaly-capillary mal-
formation syndrome31 (MIM 602501), megalencephaly-
polymicrogyria-polydactyly-hydrocephalus syndrome31
(MIM 603387), and isolated hemimegalencephaly.27,31
Described here, the preliminary analysis of a single case-
derived LCL with a heterozygous truncating mutation in
PIK3R1 suggests that the mechanism underlying SHORT
syndrome operates in an opposite manner to the above
examples, given that the spontaneously reduced phos-
phorylation of S6 seems to indicate that there is dimin-
ished function of the AKT-mTOR pathway (Figure 3).
Interestingly, constitutionally reduced signaling by the
PI3K-AKT-mTOR pathway, as demonstrated in conditions
such as Donohue syndrome (MIM 246200), and various
knockout mouse models of this pathway are associated164 The American Journal of Human Genetics 93, 158–166, July 11, 2with impaired cell division and growth retardation.
Although further analysis of cell lines from other individ-
uals with SHORT syndrome will be required for fully ascer-
taining the impact of PIK3R1mutations on the function of
the PI3K-AKT-mTOR pathway, our analysis here of a single
cell line provides a working paradigm.
In summary,we have shown that dominantmutations in
PIK3R1 cause SHORT syndrome, a recognizable malforma-
tion syndrome. Thefindings also suggest that themolecular
mechanismof the diseasemight involve downregulationof
the PI3K-AKT-mTOR pathway, which is important for
cellular proliferation and growth. It is possible that dysregu-
lationof othermembers of this complexpathwaywill result
in similar, overlapping phenotypes.
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